Introduction {#sec1_1}
============

Amyloidosis is a protein-conformational disease caused by the misfolding and aggregation of autologous protein. This protein deposits in tissues as amyloid fibrils and ultimately leads to organ architecture disruption and dysfunction. Amyloid light-chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis is associated with plasma cell disorder and monoclonal light chains in serum and/or urine. Fifteen percent of patients with AL amyloidosis have multiple myeloma, although symptomatic myeloma is unusual \[[@B1]\]. This type of amyloidosis is the prominent type involving the gastrointestinal (GI) tract. Treatment of amyloidosis is type dependent; thus, quickly reaching a diagnosis of amyloidosis and confirming its correct type are critical. At present, the overall 4-year survival rate of patients with AL amyloidosis ranges from 40 to 60%. In addition, early mortality was observed resulting from advanced cardiac damage, with approximately 30% of the patients dying within 1 year from diagnosis \[[@B2], [@B3], [@B4]\].

Monoclonal gammopathy of undetermined significance (MGUS) is the most common plasma cell disorder, and the prevalence of MGUS increases with age, from 1.7% in patients aged 50--59 years to more than 6.6% in patients aged 80 years and older \[[@B5]\]. MGUS is an asymptomatic premalignant disorder, defined by a serum monoclonal immunoglobulin concentration of \< 3 g/dL and a proportion of plasma cells in the bone marrow of \< 10% in the absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the proliferation of monoclonal plasma cells. MGUS is a known precursor of more serious diseases, such as multiple myeloma, AL amyloidosis, and Waldenström macroglobulinemia; however, most patients with MGUS do not develop a plasma cell malignancy \[[@B6]\]. The screening test for MGUS, serum protein electrophoresis, is commonly performed in patients presenting with a wide variety of clinical symptoms. Identifying true disease associations with MGUS is of major importance because it sheds light on the pathogenesis of both MGUS and the associated disorders.

The GI tract is a common site of amyloid deposition; therefore, GI involvement is common in systemic amyloidosis, while localized GI amyloidosis is rare \[[@B7]\]. However, only 30--60% of the affected individuals develop GI symptoms from the disease \[[@B1]\]. The nonspecific and vague nature of symptoms associated with different forms of amyloidosis frequently leads to delays in diagnosis when organ dysfunction is already advanced. Although GI symptoms include macroglossia, dysphagia, abdominal pain, hemorrhage, constipation, diarrhea, and malabsorption, patterns of amyloid deposition are associated with different clinical and endoscopic features \[[@B8], [@B9]\]. Amyloid deposition in the muscularis mucosae, submucosa, muscularis propria and their vessel walls is dominant in AL amyloidosis and leads to polypoid protrusions, submucosal tumor-like lesions, submucosal hematomas, ulcers, and thickening of the valvulae conniventes. Granular amyloid deposition mainly in the propria mucosae has been related to amyloid A (AA) amyloidosis, resulting in a fine granular appearance, vascular growth, mucosal friability, and erosions \[[@B7], [@B8], [@B10]\]. As a result, AL amyloidosis usually presents with constipation, mechanical obstruction, or chronic intestinal pseudo-obstruction, while AA amyloidosis presents with diarrhea and malabsorption \[[@B8]\].

Case Presentation {#sec1_2}
=================

A 72-year-old male with hypertension, diabetes mellitus, and gout was being treated by a physician in a private practice. Although the patient had no specific symptoms, he underwent a fecal occult blood testing in colon cancer screening. The test was positive, and he was further examined by colonoscopy. Some adenomatous polyps were diagnosed by biopsies; however, there were no other abnormal endoscopic findings in his colon. Two months after the initial colonoscopy, he was referred to our department for the treatment of his polyps. As expected, known polyps were successfully resected by endoscopic mucosal resection. However, there were two unexpected ulcerative lesions in his transverse colon; one was an irregularly shaped ulcer with submucosal hematoma (Fig. [1a, b](#F1){ref-type="fig"}), and the other was a sharply marginated ulcer with slight submucosal hematoma (Fig. [1c, d](#F1){ref-type="fig"}). Histological examinations of biopsy specimens of these lesions and the endoscopically resected polyps revealed deposition of eosinophilic, homogeneous, and amorphous material mainly in the submucosal blood vessel walls of the colon using hematoxylin-eosin staining (Fig. [2a](#F2){ref-type="fig"}) and Congo red (Fig. [2b](#F2){ref-type="fig"}). Immunohistochemically, the deposits were positive for amyloid P (Fig. [2c](#F2){ref-type="fig"}) and λ light chain (Fig. [2d](#F2){ref-type="fig"}), and negative for AA (Fig. [2e](#F2){ref-type="fig"}) and κ light chain (Fig. [2f](#F2){ref-type="fig"}), indicating λ-light-chain restriction. Although an esophagogastroduodenoscopy showed no abnormal findings, the same kind of deposits was also found mainly in the mucosal stroma and blood vessel walls of biopsy specimens of the stomach (Fig. [2g](#F2){ref-type="fig"}), which were positive for Congo red (Fig. [2h](#F2){ref-type="fig"}), amyloid P (Fig. [2i](#F2){ref-type="fig"}), and λ light chain (Fig. [2j](#F2){ref-type="fig"}), and negative for AA (Fig. [2k](#F2){ref-type="fig"}) and κ light chain (Fig. [2l](#F2){ref-type="fig"}). The direct Fast Scarlet stained the deposits an orange-red color (data not shown). To investigate the cause and progression of his amyloidosis minutely, we specifically examined his blood, bone marrow (Fig. [3](#F3){ref-type="fig"}), and urine (Table [1](#T1){ref-type="table"}). Immunofixation electrophoresis showed M-proteins for anti-IgG-λ in the serum and λ-type Bence-Jones protein in the urine. A serum-free light-chain assay indicated a decreased κ chain, an elevated λ chain, and an abnormal κ/λ ratio. According to "Diagnostic criteria for plasma cell disorders" \[[@B11]\], he was diagnosed as having non-IgM (IgG-λ) MGUS. Using this information, we made a definitive diagnosis of systemic AL amyloidosis caused by MGUS. ^18^F-Fluorodeoxyglucose positron emission tomography/computed tomography showed no abnormal ^18^F-Fluorodeoxyglucose uptake anywhere in his body.

Abnormally high levels of N-terminal pro-brain natriuretic peptide and thyroid-stimulating hormone and a low level of free thyroxin were suspected to be potential abnormal values of his amyloidosis. Although he had no cardiac manifestations at that point, the patient\'s low ejection fraction (48%) was confirmed by echocardiography, and a coronary angiography revealed multivessel stenosis. After the patient underwent coronary artery stenting, his cardiac function is gradually improving. Hereafter, a combination therapy with bortezomib, lenalidomide, and dexamethasone for MGUS is planned, but we will strictly monitor his condition and carefully determine indications for treatment.

Discussion {#sec1_3}
==========

We describe a case of systemic AL amyloidosis caused by MGUS, which was incidentally recognized at the time of endoscopic resection of the patient\'s colon polyps. A fecal occult blood test used in colon cancer screening led to the early detection of the patient\'s disorder. Two months before detection, there were no endoscopic findings of amyloidosis in his colon. Presumably, during this brief period, the colonic ulcerative lesions developed rapidly. In addition, one lesion was an irregularly shaped ulcer with submucosal hematoma, and the other was a sharply marginated ulcer with slight submucosal hematoma. These findings potentially reflect the time-dependent change and healing process of ulcerative intestinal lesions of AL amyloidosis. The endoscopic findings of ulcer and submucosal hematoma observed in the colon of this patient are characteristic of AL amyloidosis, as described above \[[@B8], [@B9]\]. Submucosal hematomas correlate with vessel friability caused by amyloid deposits of the vessel walls, which were also confirmed in histological examinations of the present case. Ulcers are thought to be secondary mucosal damage resulting from hematomas.

James et al. \[[@B12]\] revealed that nearly three-fourths (12/17; 71%) of the patients with AL amyloidosis of the luminal GI tract had abnormal findings on endoscopic examination. Mucosal erosions or ulcerations (6/17; 35%) and submucosal hematomas (6/17; 35%) were the most common endoscopic findings. They reported the endoscopic finding of a submucosal hematoma as a distinctive finding for AL amyloid involvement of the luminal GI tract in the setting of GI bleeding. Physicians should consider underlying AL amyloidosis when detecting submucosal hematomas of the GI tract on endoscopic examination.

AL amyloidosis is largely a disease of the elderly that has been increasing in incidence as the population ages. Clonal proliferations of plasma cells, termed plasma cell dyscrasias, serve as the precursor state to AL amyloidosis. The concentration of immunoglobulin light chains is important; the long-term risk of developing AL amyloidosis in patients with MGUS is estimated to be 0.8% \[[@B13]\], whereas the risk associated with multiple myeloma has been estimated as high as 38% \[[@B14]\].

The treatment of AL amyloidosis includes myeloma-type chemotherapy and high-dose chemotherapy with hematopoietic stem cell transplantation. By suppressing the plasma cell clones, chemotherapy reduces the concentration of toxic light chains, which is necessary to improve organ function and prolong survival \[[@B15]\]. However, AL amyloidosis is not merely a hematologic malignancy; amyloid-related dysfunction of one or more organs determines survival and limits patient access to aggressive treatments. Therefore, treatment requires a risk-adapted approach with dose reductions and schedule modifications of chemotherapy regimens and a close monitoring of hematologic and organ responses. Recently, novel chemotherapy agents have become available, and bortezomib-containing regimens have achieved high hematologic response rates and can be effective treatments for severe cardiac AL amyloidosis \[[@B2]\]. Although this patient has not reported any symptoms and has not yet been examined for amyloid deposition in his cardiac tissue, his cardiac function has already decreased. After coronary artery stenting, his cardiac function is improving. Therefore, in the future, combination therapy with bortezomib, lenalidomide, and dexamethasone for MGUS is planned. Through the relatively early detection and treatment of his disorder, we hope to improve his prognosis.

In conclusion, this is a case report of systemic AL amyloidosis caused by MGUS, which was incidentally detected by colonoscopy. We describe characteristic and intriguing endoscopic findings of AL amyloidosis.
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![Colonoscopic images of AL amyloidosis. A colonoscopy revealed two types of ulcerative lesions in the transverse colon; an irregularly shaped ulcer with submucosal hematoma (**a**, **b**) and a sharply marginated ulcer with slight submucosal hematoma (**c**, **d**). These lesions presumably reflect a time-dependent change of colonic findings of AL amyloidosis (**b**, **d**: with indigo carmine dye spraying).](crg-0012-0737-g01){#F1}

![Pathological findings of AL amyloidosis in the colon (**a--f**) and stomach (**g--l**). Histological examinations revealed deposition of eosinophilic, homogeneous, and amorphous material in the submucosal blood vessel walls of the colon (**a**), which was positive for Congo red (**b**). Immunohistochemically, the deposits were positive for amyloid P (**c**) and λ light chain (**d**), and negative for AA (**e**) and κ light chain (**f**). The same types of deposits were found in the mucosal stroma and blood vessel walls of the stomach (**g**), and were positive for Congo red (**h**), amyloid P (**i**), and λ light chain (**j**), and negative for AA (**k**) and κ light chain (**l**). (**a**, **g** hematoxylin-eosin staining; **b**, **h** Congo red staining; **c**, **i** anti-amyloid P staining; **d**, **j** anti-λ light chain staining; **e**, **k** anti-AA staining; **f**, **j** anti-κ light chain staining.)](crg-0012-0737-g02){#F2}

![Bone-marrow findings of MGUS. Bone marrow showed only mild plasmacytosis (\< 10% of the nucleated cells).](crg-0012-0737-g03){#F3}

###### 

The patient\'s laboratory data

  **CBC**                                **Immunologic test**         
  ---------------------- --------------- ---------------------------- -------------------
  White blood cell       51×10^2^/µL     IgG                          1541 mg/dL
  Blast                  0%              IgA                          94 mg/dL
  Atypical lymphocyte    0%              IgM                          26 mg/dL
  Red blood cell         411×10^4^/µL    IgD                          \<1 mg/dL
  Hemoglobin             12.1 g/dL       CH50                         57 U/mL
  Hematocrit             36.4 %          Antinuclear antibody         (--)
  Platelet               16.5×10^4^/µL   Rheumatoid factor            \<5 IU/mL
  Coagulation test                       β2-microglobulin             2.2 mg/L
  PT%                    103.3%          sIL-2R                       270 U/mL
  PT-INR                 0.98            Serum protein fraction       
  APTT                   27.8 s          Albumin fraction             64.8% (4.99 g/dL)
  **Biochemistry**                       α1-globulin fraction         2.9% (0.22 g/dL)
  Total protein          7.7 g/dL        α2-globulin fraction         9.6% (0.74 g/dL)
  Albumin                5.0 g/dL        β-globulin fraction          6.2% (0.48 g/dL)
  A/G ratio              1.85            γ-globulin fraction          16.5% (1.27 g/dL)
  AST                    21 U/L          M-bow                        (+)
  ALT                    22 U/L          **Immunoelectrophoresis**    
  LDH                    120 U/L         IFE (M-protein)              (+): IgG-λ
  Alkaline phosphatase   174 U/L         IFE (urinary BJP)            (+): λ
  γ-GTP                  36 U/L          **Serum-free light chain**   
  Total bilirubin        0.3 mg/dL       [k]{.smallcaps} chain        12.7 mg/L
  Creatine kinase        88 U/L          λ chain                      168 mg/L
  Amylase                68 U/L          [k/]{.smallcaps}λ            0.076
  Triglyceride           399 mg/dL       BM examination               
  Total cholesterol      126 mg/dL       Nucleated-cell count         25000/µL
  Cholinesterase         207 U/L         Myeloid/erythroid            1.6
  Creatinine             0.91 mg/dL      Blast                        0.4%
  Blood urea nitrogen    19 mg/dL        Promyelocyte                 0.5%
  Uric acid              4.8 mg/dL       Myelocyte                    11.6%
  C-reactive protein     0.118 mg/dL     Metamyelocyte                3.5%
  Fe                     72 µg/dL        Plasma cell                  5.2%
  Ferritin               113 ng/mL       G-banding (MM/PL)            NP
  Calcium                9.8 mg/dL                                    
  TSH                    8.28 µIU/mL     **Urine test**               
  Free thyroxin          0.83 ng/dL      Protein                      (--)
  Hemoglobin A1c         6.4%            Sugar                        (--)
  NT-proBNP              999 pg/mL       Occult blood                 (--)

CBC, complete blood cell count; PT, prothrombin time; PT-INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; A/G ratio, albumin-globulin ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; γ-GTP, γ-glutamyl transpeptidase; TSH, thyroid-stimulating hormone; NT-proBNP, N-terminal pro-brain natriuretic peptide; CH50, 50% hemolytic complement; sIL-2R, soluble interleukin-2 receptor; IFE, immunofixation electrophoresis; BJP, Bence-Jones protein; BM, bone marrow; MM, multiple myeloma; PL, plasmacytic leukemia; NP, not particular.
